Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT/QTc Study of TAS5315 in Healthy Adults
jRCT2071220108Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAS5315 (4 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in QTcF: TAS5315 vs placebo. Started Mar 2023; status: completed.
02
Drugs
TAS5315
Beyond the preview
Go deeper on jRCT2071220108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220108.